Waltham, MA 9/6/18; Franklin Lakes, NJ 9/7/18—Thermo Fisher Scientific has agreed to acquire Becton, Dickinson’s (BD) Advanced Bioprocessing business for an undisclosed amount. With revenues of $100 million, the business provides technical services and a variety of peptones for cell culture-media formulation. The Advanced Bioprocessing business will join Thermo Fisher’s Life Sciences Solutions Segment.

“The addition of these new capabilities will complement our bioproduction offering and strengthen our ability to serve this rapidly growing market, from development to large-scale production,” commented Mark Stevenson, executive vice president and COO of Thermo Fisher. “BD remains committed to our customers in the clinical, life sciences and industrial segments, and will continue to sell all of our media product offerings to these important partners,” stated Patrick Kaltenbach, president of Life Sciences for BD. The transaction is expected to close in early 2019. The Advanced Bioprocess business is anticipated to contribute $0.13–$0.15 to BD’s fiscal 2018 EPS.

The Advanced Processing business provides cell culture supplements, peptones (which optimize media performance) and media. Its brands include BD Recharge, BD Resurge, BD Select and BD Cell. The acquisition adds to Thermo Fisher’s existing product lines, enhancing its offering for biologics manufacturing.